Today is a very sad day. Sir John Gurdon was a titan of developmental biology. Gurdon’s foundational research, culminating in his Nobel Prize recognition in 2012, was a great source of inspiration to me as a university student at the time www.cam.ac.uk/research/new...

Great recognition to a fundamental discovery that reshaped modern #immunology. Congrats to the laureates! However, imho the Nobel committee missed the chance to acknowledge an additional key contributor to the understanding of #Foxp3 and #Treg functionality

Elegant piece by @cedric-blanpain.bsky.social in @natrevcancer.nature.com especially highlighting the recent advances of potential #therapeutic strategies to target #EMT tumor states www.nature.com/articles/s41...

Monte Rosa Therapeutics $GLUE announces collaboration with Novartis for molecular glue #degraders to treat immune-mediated diseases 2nd partnership between the 2 companies, now including $120M upfront and up to $5.7 billion total deal #biotech #immunology www.globenewswire.com/news-release...

Thrilled to have contributed to the oversubscribed $67M Series B round of NRG Therapeutics NRG is pioneering first-in-class therapies targeting #mitochondrial dysfunction for the treatment of devastating #neurodegenerative diseases such as ALS and Parkinson’s www.globenewswire.com/news-release...

Gilead's Kite enters the in vivo #CART space with $350 million Interius buyout #biotech #pharma #celltherapy www.kitepharma.com/news/press-r...

And the whispers were going in the right direction: AbbVie to acquire Gilgamesh bretisilocin, a novel, investigational therapy for major #depressive disorder, expanding its #psychiatry pipeline Total deal up to $1.2 billion #pharma #innovation #biotech news.abbvie.com/2025-08-25-A...

Novo’s Wegovy becomes first #GLP1 drug approved for MASH The only other therapy approved for #MASH, Madrigal Rezdiffra, has gotten off to a stronger-than-expected sales start: $180m in net sales in 2024, $350m over H1 2025, $1b projected annual sales in 2026 www.biopharmadive.com/news/novo-we...

Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class #melanocortin receptor targeted treatment for patients with #retinal diseases Total deal up to €280 million www.globenewswire.com/news-release...

Skyhawk Therapeutics announces #strategic collaboration with Merck KGaA to discover novel #RNA targeting small molecules for #neurological disorders Total deal value exceeds $2 billion www.prnewswire.com/news-release...

Daiichi Sankyo and Merck B7-H3 targeted #ADC I-DXd (ifinatamab deruxtecan) granted FDA #Breakthrough Therapy Designation for pretreated extensive-stage SCLC www.merck.com/news/ifinata...

BMS EGFRxHER3 #bispecific #ADC iza-bren granted FDA #Breakthrough Therapy Designation for previously treated advanced EGFR-mutated NSCLC news.bms.com/news/details...

Pfizer’s #sicklecell disease drug inclacumab (P-selectin inhibitor) has flunked a key phase 3 test, the latest blow to the pharma’s $5.4 billion acquisition of Global Blood Therapeutics Thrive-131 missed its primary endpoint at 48 weeks www.pfizer.com/news/announc...

Encouraging phase 1 results of an off-the-shelf, lymph node targeted #cancer vaccine targeting common #KRAS mutations (G12D, G12R) in pancreatic and colorectal cancer from Elicio $ELTX, @mskcancercenter.bsky.social, @mdanderson.bsky.social‪‬, UCLA & clinical collabs www.nature.com/articles/s41...

Superluminal Medicines announces collaboration with Eli #Lilly to advance small molecule #therapeutics (undisclosed GPCR targets) for #cardiometabolic diseases and #obesity Total deal of up to $1.3 billion www.prnewswire.com/news-release...

Bayer and Kumquat Biosciences enter global exclusive #license and #collaboration to develop and commercialize Kumquat's #KRAS G12D inhibitor. Phase 1a study will initiate H2 2025 Total deal up to $1.3 billion #oncology #pharma #oncogene #therapeutics www.prnewswire.com/news-release...

Novartis is closer to bringing the first targeted #drug to market for Sjogren’s disease Ianalumab, a dual mechanism, #Bcell depleting antibody that targets BAFF-R, originated from #Morphosys collaboration #immunology #innovation #biopharma www.novartis.com/news/media-r...

Abbvie is in talks to acquire Gilgamesh Pharmaceuticals, a biotech company that’s developing next-generation psychedelic compounds for mental health disorders www.reuters.com/legal/transa...

GSK and Hengrui enter agreements to develop up to 12 innovative drugs across respiratory, #immunology & #inflammation and #oncology Includes license for potential best-in-class PDE3/4 inhibitor in clinical dev for COPD $500 million upfront, up to $12 billion total deal www.gsk.com/en-gb/media/...

Gate enters into a collab & license agreement w #Lilly to discover/develop molecular gate medicines > #smallmolecules that can eliminate disease-causing proteins modulating the secretory translocon Undisclosed upfront & equity investment, total deal up to $856m www.businesswire.com/news/home/20...

French biotech Abivax $ABVX has announced positive Phase 3 results for obefazimod, its first-in-class oral miR-124 enhancer, in moderate to severely active ulcerative colitis ir.abivax.com/news-release...

Roche has axed one of the #obesity assets from its $2.7 billion Carmot buyout. The dropped candidate, CT-173, is a long-acting PYY analog in preclinical dev Carmot’s former lead asset CT-388, a GLP-1/GIP agonist, is pending a go decision for Ph3 in obesity www.fiercebiotech.com/biotech/roch...

Matchpoint Therapeutics announces exclusive option and license agreement with #Novartis to develop oral #covalent inhibitors directed at an undisclosed transcription factor linked to several inflammatory diseases $60 million upfront and up to $1 billion total deal matchpointtx.com/news/matchpo...

Dispatch Bio emerges to develop a sequential gene & cell therapy for solid tumors 1) Engineered virus targets cancer cells > exposes antigen 🔥 2) CAR-T seeks out the antigen 3) Cancer cells are killed > release viral particles + antigen > flag nearby tumor > ♻️ www.biopharmadive.com/news/disptac...

Very encouraging news from Minoryx, one of my former #biotech portfolio companies Minoryx is one step closer to achieving approval for leriglitazone (NEZGLYAL) as the only pharmacological treatment for patients suffering from #cALD, a devastating #orphan disease www.minoryx.com/media/lerigl...

Sanofi to acquire Vicebio for $1.15 billion upfront to expand #respiratory vaccines pipeline Vicebio is a London-based #biotech with an early clinical-stage non-mRNA combination #vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) www.sanofi.com/en/media-roo...

Sino Biopharma to acquire its Chinese peer LaNova Medicines, which previously secured licensing deals with #Merck (anti-VEGF x PD1 bispecific antibody in Ph1/2 in solid tumors) and #AstraZeneca (anti-GPRC5D ADC in Ph1/2 in r/r MM) Total deal up to $951 million www.fiercebiotech.com/biotech/sino...

AbbVie and IGI announce exclusive global #licensing agreement for ISB 2001, a first-in-class CD38 × BCMA × CD3 trispecific #antibody that is currently in Phase 1 for r/r multiple myeloma $700 m upfront and up to $1.225 bn in milestones #pharma #oncology #deal news.abbvie.com/2025-07-10-A...

This is a great example of the kind of revenue generating assets that #pharma companies facing major #patent cliffs will need in the coming years

Merck to acquire Verona Pharma for $10 billion to expand its #cardio pulmonary pipeline. The deal includes Ohtuvayre (ensifentrine), a first-in-class dual inhibitor of PDE3/4, approved for the maintenance treatment of #COPD in adults #pharma #biotech #deal www.merck.com/news/merck-t...

Lilly to acquire Verve to advance genetic medicines for cardiovascular disease. $LLY will pay $1 bn at closing, for a total aggregate deal value of up to $1.3 billion Proud investor in $VERV #pharma #biotech #deal #cardio #geneediting investor.lilly.com/news-release...

Regeneron $REGN in-licenses HS-20094, a clinical-stage dual GLP-1/GIP receptor agonist, from Hansoh Pharma. A Ph3 in #obesity in China and Ph2b trial in #diabetes are ongoing $80 million upfront, with potential additional payments of up to $1.93 billion investor.regeneron.com/news-release...

BioNTech and Bristol Myers Squibb @bristolmyerssquibb.bsky.social enter global strategic #partnership to advance BNT327 (PD-L1 x VEGF-A bispecific #antibody) & #oncology leadership

BioNTech partners with BMS to co-develop & co-commercialize BNT327, a PD-L1 x VEGF-A bispecific #antibody, for multiple solid tumors. $1.5 billion upfront, in a deal that could potentially exceed $11 billion #oncology #deal #pharma investors.biontech.de/news-release...

Sanofi to acquire Blueprint Medicines $BPMC for $9.1 billion #immunology #deal #pharma #biotech www.sanofi.com/en/media-roo...

Another China to West #oncology deal! Pfizer has entered into an exclusive global, ex-China, licensing deal with 3SBio for SSGJ-707, a bispecific PD-1 x VEGF #antibody. Phase 3 to initiate in #China in 2025 $1.25 billion upfront and up to $4.8 billion in milestones www.pfizer.com/news/press-r...

Novo Nordisk CEO to step down, presumably following the recent sharp drop in $NVO share price and to help steer Novo’s strategy amid the growing competition in the #obesity drug market www.cnbc.com/2025/05/16/n...

FDA has approved EMRELIS™ (telisotuzumab vedotin-tllv), a c-Met-directed #ADC conjugated with MMAE, for adults with previously treated advanced #NSCLC with high c-Met protein overexpression news.abbvie.com/2025-05-14-U...

Excited to be attending the 25th #BioEquityEurope in Bruges! Looking forward to reconnecting with fellow investors and #biotech colleagues across the life sciences ecosystem. Feel free to reach out if you'd like to connect during the event! #venturecapital #lifesciences

Congrats to our portfolio company AbolerIS Pharma for dosing the first cohort of their Phase 1 trial for ABO21009! We led the Series A with the goal of bringing this new class of immunomodulatory therapies to patients, and it is fantastic to see this happening now www.prnewswire.com/news-release...

Happy to announce the launch of Adaptam Therapeutics, a new #biotech company pioneering #cancer immunotherapies by disrupting the immunosuppressive #myeloid TME through glyco-immune checkpoints to treat solid tumors I’m proud to be a founding member and to have led its incubation as Board Director

Ari Melnick has been appointed as the new Director of the Barcelona @carrerasijc.bsky.social #leukaemia research institute, joining from Weill Cornell Medicine in New York www.carrerasresearch.org/en/news/dr-a...

AstraZeneca is establishing a new global R&D centre in Beijing, signing two collab agreements w Harbour Bio (multi-specific abs) and Syneron Bio (macro-cyclic peptides), and launching a new joint venture w BioKangtai (vaccines for respiratory/infectious diseases) www.astrazeneca.com/media-centre...

Harbour BioMed enters into a global strategic collaboration with AstraZeneca to discover and develop next-gen multi-specific antibodies for immunology, oncology & beyond. The collab includes an option to license multiple programs & a $105M equity investment by AZ www.harbourbiomed.com/news/239.html

Alnylam $ALNY receives FDA approval of its #RNAi therapeutic AMVUTTRA® (vutrisiran) for adults with ATTR amyloidosis with cardiomyopathy (ATTR-CM) investors.alnylam.com/press-releas...

Sanofi acquires Dren Bio’s bispecific myeloid cell engager for B cell depletion for $600M upfront (up to $1.3B) This reinforces pharma’s interest in T/B cell depleting strategies for I&I & the upcoming wave of exploiting myeloid cell biology for therapeutics www.globenewswire.com/news-release...

AITHYRA launches as a new research institute for biomedical artificial intelligence in Vienna, aiming to combine the best of academia, industry and startups. Led by @georgwinter.bsky.social and @mmbronstein.bsky.social as Scientific Directors of Life Sciences and AI. www.oeaw.ac.at/aithyra

Fantastic evening supporting the first lecture organized by #CaixaResearchInstitute and catching up with many colleagues! It’s always inspiring to hear Gabi as he guides us through a ‘sweet’ path at the intersection of #glycobiology and #immunology with tremendous potential for human diseases.

AbbVie enters the #obesity race with the licensing of Gubra’s long-acting #amylin peptide analog, GUB014295, currently in Phase 1 $350 million upfront and up to $1.9 billion in milestones news.abbvie.com/2025-03-03-A...

Summit announces a clinical collaboration with #Pfizer to evaluate ivonescimab, its PD1 x VEGF bispecific antibody, in combination with multiple Pfizer vedotin-based ADCs for solid tumors No financial terms or potential first-option rights are disclosed www.smmttx.com/pressrelease...